Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity

Abstract

Anti-tuberculosis (AT) medications, including isoniazid (INH), can cause drug-induced liver injury (DILI), but the underlying mechanism remains unclear. In this study, we aimed to identify genetic factors that may increase the susceptibility of individuals to AT-DILI and to examine genetic interactions that may lead to isoniazid (INH)-induced hepatotoxicity. We performed a targeted sequencing analysis of 380 pharmacogenes in a discovery cohort of 112 patients (35 AT-DILI patients and 77 controls) receiving AT treatment for active tuberculosis. Pharmacogenome-wide association analysis was also conducted using 1048 population controls (Korea1K). NAT2 and ATP7B genotypes were analyzed in a replication cohort of 165 patients (37 AT-DILI patients and 128 controls) to validate the effects of both risk genotypes. NAT2 ultraslow acetylators (UAs) were found to have a greater risk of AT-DILI than other genotypes (odds ratio [OR] 5.6 [95% confidence interval; 2.5–13.2], P = 7.2 × 10⁻⁶). The presence of ATP7B gene 832R/R homozygosity (rs1061472) was found to co-occur with NAT2 UA in AT-DILI patients (P = 0.017) and to amplify the risk in NAT2 UA (OR 32.5 [4.5–1423], P = 7.5 × 10⁻⁶). In vitro experiments using human liver-derived cell lines (HepG2 and SNU387 cells) revealed toxic synergism between INH and Cu, which were strongly augmented in cells with defective NAT2 and ATP7B activity, leading to increased mitochondrial reactive oxygen species generation, mitochondrial dysfunction, DNA damage, and apoptosis. These findings link the co-occurrence of ATP7B and NAT2 genotypes to the risk of INH-induced hepatotoxicity, providing novel mechanistic insight into individual AT-DILI susceptibility.

Genetic factors amplify tuberculosis drug-induced liver injury risk

Tuberculosis is a major health issue, with the bacterium Mycobacterium tuberculosis causing illness and death globally. A key challenge in treating TB is the liver damage caused by drugs used in treatment, particularly isoniazid, which can lead to severe liver injury. While genetic factors like the NAT2 gene have been linked to this drug-induced liver injury, the exact reasons why some people are more susceptible remain unclear. Researchers found that certain genetic variants, particularly in the NAT2 gene and another gene called ATP7B, were more common in patients who suffered liver injury. In conclusion, the research advances our understanding of how genetics can influence the risk of liver injury from TB drugs. This knowledge could lead to more personalized treatment plans and safer TB management in the future. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.